Showing 441-450 of 18069 results for "".
Using CGMs and Insulin Pumps to Treat Pediatric Patients with T1D
https://reachmd.com/programs/diabetes-discourse/using-cgms-and-insulin-pumps-to-treat-pediatric-patients-with-t1d/16366/Tune in to learn more about some of the latest technologies used to treat pediatric patients with type 1 diabetes.Diabetes Alert Day: Spreading Awareness & Education
https://reachmd.com/programs/diabetes-discourse/diabetes-alert-day-spreading-awareness-education/13531/With Diabetes Alert Day around the corner, what do we need to know about this campaign?Preventive Heart Disease Therapies for Diabetics
https://reachmd.com/programs/clinicians-roundtable/preventive-heart-disease-therapies-for-diabetics/1585/People with diabetes are two to four times more likely to develop cardiovascular disease. How can you help your patients reduce the odds of getting cardiovascular disease? Join host Larry Kaskel interview Cleveland Clinic's Stanely Hazen.The Doctor and the Mother: Treating Neonatal Diabetes
https://reachmd.com/programs/clinicians-roundtable/the-doctor-and-the-mother-treating-neonatal-diabetes/1692/Dr. Louis Philipson, from the University of Chicago School of Medicine, discusses the treatment of Neonatal Diabetes in context of a special case involving patient Lily Jaffe. Lilly's mother, Laurie Jaffe, a strong advocate for research and advancement in the treatment of this disease, participatesDrug Delivery Systems in the Management of Diabetes
https://reachmd.com/programs/diabetes-discourse/drug-delivery-systems-in-the-management-of-diabetes/4844/New drug delivery technologies are changing one of the key therapeutic challenges of insulin delivery in the management of diabetes. Join guest host Dr. Candis Morello and her guest, Dr. Brookie Best, assistant clinical professor of pharmacy and pediatrics at University of California San Diego, as tHome Monitoring of Blood Sugar Did Not Improve Glycemic Control After 1 Year
https://reachmd.com/programs/the-jama-report/home-monitoring-blood-sugar-did-not-improve-glycemic-control-after-1-year/9653/A study in JAMA suggests that self-monitoring should not be routine in patients with type 2 diabetes who are not treated with insulinUnfair Treatment of Phase I Clinical Trial Subjects
https://reachmd.com/programs/clinicians-roundtable/unfair-treatment-of-phase-i-clinical-trial-subjects/3395/Dr. Jonathan Kimmelman, assistant professor of the Biomedical Research unit at McGill University, discusses with host Dr. Maurice Pickard what appears to be a ‘job' that may exploit the underclass in Phase 1 clinical studies. The poor in the studies are less likely to have access to the drugs when aKey Insights from GRADE: Exploring Data on Glycemia Reduction in T2D
https://reachmd.com/programs/diabetes-discourse/key-insights-from-grade-exploring-data-on-glycemia-reduction-in-t2d/14619/What did we learn about treatment options for patients with type 2 diabetes from the GRADE study?Diabetes Research Suggests Better Long Term Outcomes with Early Insulin
https://reachmd.com/programs/everyday-family-medicine/diabetes-research-suggests-better-long-term-outcomes-with-early-insulin/7754/Host Jennifer Caudel, DO welcomes Jay Shubrook, DO, Director of Clinical Research and Diabetes Services at Touro University-California College of Osteopathic Medicine. Recorded on site at the American Osteopathic Association's annual medical education conference, Dr. Shubrook discusses a pilot studSotagliflozin in HFpEF Without Diabetes: Inside the SOTA-P-CARDIA Trial from AHA 2025
https://reachmd.com/clinical-practice/cardiology/sotagliflozin-in-hfpef-without-diabetes-inside-the-sota-p-cardia-trial-from-aha-2025/39898/SOTA-P-CARDIA shows sotagliflozin improves LV mass, exercise capacity, and quality of life in non-diabetic HFpEF, supporting dual SGLT1/2 inhibition.